Open AccessRisk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis
Author(s) -
Elizaveta Efuni,
Samuel Cytryn,
Patrick M. Boland,
Timothy B. Niewold,
Anna C. Pavlick,
Jeffrey S. Weber,
Sabina Sandigursky
Publication year - 2020
Publication title -
journal of clinical rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.615
H-Index - 50
eISSN - 1536-7355
pISSN - 1076-1608
DOI - 10.1097/rhu.0000000000001314
Subject(s) - medicine , rheumatoid arthritis , discontinuation , adverse effect , malignancy , oncology
Immune checkpoint inhibitors (ICIs) are increasingly used to treat advanced cancer. Rheumatoid arthritis (RA) is associated with an increased risk of malignancies; however, patients with RA have been excluded from ICI trials. In this study, we evaluated risk of toxicity after initiation of ICI treatment in RA patients.